{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:33:45Z","timestamp":1760056425599,"version":"build-2065373602"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.diagmicrobio.2018.09.011","type":"journal-article","created":{"date-parts":[[2018,10,2]],"date-time":"2018-10-02T18:47:17Z","timestamp":1538506037000},"page":"167-170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["In vitro activity of telavancin against Staphylococcus aureus causing pneumonia or skin and skin structure infections with concomitant bloodstream infections in United States hospitals (2012\u20132016)"],"prefix":"10.1016","volume":"93","author":[{"given":"Leonard R.","family":"Duncan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert K.","family":"Flamm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo E.","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2018.09.011_bb0005","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1093\/jac\/dkx437","article-title":"Telavancin for refractory MRSA bacteraemia in intermittent haemodialysis recipients","volume":"73","author":"Britt","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.09.011_bb0010","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1128\/AAC.00617-15","article-title":"Case-control study of telavancin as an alternative treatment for gram-positive bloodstream infections in patients with cancer","volume":"60","author":"Chaftari","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.09.011_bb0015","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard","article-title":"M07Ed11E","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2018"},{"key":"10.1016\/j.diagmicrobio.2018.09.011_bb0020","series-title":"Performance standards for antimicrobial susceptibility testing: 28th informational supplement","article-title":"M100Ed28E","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2018"},{"issue":"Suppl. 4","key":"10.1016\/j.diagmicrobio.2018.09.011_bb0025","doi-asserted-by":"crossref","first-page":"S254","DOI":"10.1086\/598186","article-title":"Staphylococcus aureus bloodstream infections: definitions and treatment","volume":"48","author":"Corey","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.09.011_bb0030","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/cid\/ciu971","article-title":"Potential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on Staphylococcus aureus","volume":"60","author":"Corey","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 5","key":"10.1016\/j.diagmicrobio.2018.09.011_bb0035","doi-asserted-by":"crossref","first-page":"S386","DOI":"10.1086\/533595","article-title":"Management of methicillin-resistant Staphylococcus aureus bacteremia","volume":"46","author":"Cosgrove","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 12","key":"10.1016\/j.diagmicrobio.2018.09.011_bb0040","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/01.ccm.0000509363.39114.5c","article-title":"Telavancin observational use registry: preliminary results for bacteremia and endocarditis","volume":"44","author":"Friedman","year":"2016","journal-title":"Crit Care Med"},{"key":"10.1016\/j.diagmicrobio.2018.09.011_bb0045","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/phar.1577","article-title":"Clinical implications of vancomycin heteroresistant and intermediately susceptible Staphylococcus aureus","volume":"35","author":"Gomes","year":"2015","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.diagmicrobio.2018.09.011_bb0050","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1128\/AAC.49.3.1127-1134.2005","article-title":"Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus","volume":"49","author":"Higgins","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.09.011_bb0055","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1001\/jama.2014.9743","article-title":"Clinical management of Staphylococcus aureus bacteremia: a review","volume":"312","author":"Holland","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.diagmicrobio.2018.09.011_bb0060","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1053\/jhin.2002.1270","article-title":"Importance of focus identification in the treatment of Staphylococcus aureus bacteraemia","volume":"52","author":"Jensen","year":"2002","journal-title":"J Hosp Infect"},{"key":"10.1016\/j.diagmicrobio.2018.09.011_bb0065","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ccc.2013.03.008","article-title":"Staphylococcus aureus bacteremia, risk factors, complications, and management","volume":"29","author":"Keynan","year":"2013","journal-title":"Crit Care Clin"},{"key":"10.1016\/j.diagmicrobio.2018.09.011_bb0070","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/01.CCM.0000119424.31648.1E","article-title":"Severe bloodstream infections: a population-based assessment","volume":"32","author":"Laupland","year":"2004","journal-title":"Crit Care Med"},{"key":"10.1016\/j.diagmicrobio.2018.09.011_bb0075","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1469-0691.2012.03903.x","article-title":"The changing epidemiology of Staphylococcus aureus bloodstream infection: a multinational population-based surveillance study","volume":"19","author":"Laupland","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diagmicrobio.2018.09.011_bb0080","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00281-17","article-title":"Comparative pharmacodynamics of telavancin and vancomycin in the neutropenic murine thigh and lung infection models against Staphylococcus aureus","volume":"61","author":"Lepak","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.09.011_bb0085","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1128\/JCM.00611-15","article-title":"Analysis of vancomycin susceptibility testing results for presumptive categorization of telavancin","volume":"53","author":"Mendes","year":"2015","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2018.09.011_bb0090","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s10096-016-2865-8","article-title":"Update of the activity of telavancin against a global collection of Staphylococcus aureus causing bacteremia, including endocarditis (2011-2014)","volume":"36","author":"Mendes","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.09.011_bb0095","series-title":"ID Week, October 4-8 San Diego, CA, USA: # 1861","article-title":"Clinical experience with telavancin for the treatment of patients with bacteremia and endocarditis: Preliminary results from the telavancin observational use registry (TOUR\u2122)","author":"Reilly","year":"2017"},{"key":"10.1016\/j.diagmicrobio.2018.09.011_bb0100","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3810\/pgm.2014.09.2811","article-title":"Staphylococcus aureus bacteremia: targeting the source","volume":"126","author":"Rongpharpi","year":"2014","journal-title":"Postgrad Med"},{"issue":"Suppl. 1","key":"10.1016\/j.diagmicrobio.2018.09.011_bb0105","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.ijantimicag.2008.06.006","article-title":"Staphylococcus aureus bacteraemia with known sources","volume":"32","author":"Rubinstein","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2018.09.011_bb0110","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3109\/00365548.2014.995696","article-title":"Telavancin for refractory methicillin-resistant Staphylococcus aureus bacteremia and infective endocarditis","volume":"47","author":"Ruggero","year":"2015","journal-title":"Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.09.011_bb0115","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijantimicag.2013.06.003","article-title":"Telavancin versus vancomycin for bacteraemic hospital-acquired pneumonia","volume":"42","author":"Stryjewski","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2018.09.011_bb0120","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/1471-2334-14-289","article-title":"A randomized phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study","volume":"14","author":"Stryjewski","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.09.011_bb0125","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1128\/CMR.00134-14","article-title":"Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management","volume":"28","author":"Tong","year":"2015","journal-title":"Clin Microbiol Rev"},{"author":"VIBATIV Package Insert","key":"10.1016\/j.diagmicrobio.2018.09.011_bb0130"},{"key":"10.1016\/j.diagmicrobio.2018.09.011_bb0135","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jhin.2011.05.013","article-title":"Trends in sources of meticillin-resistant Staphylococcus aureus (MRSA) bacteraemia: data from the national mandatory surveillance of MRSA bacteraemia in England, 2006-2009","volume":"79","author":"Wilson","year":"2011","journal-title":"J Hosp Infect"},{"key":"10.1016\/j.diagmicrobio.2018.09.011_bb0140","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s40121-017-0162-1","article-title":"Telavancin in the treatment of concurrent Staphylococcus aureus bacteremia: a retrospective analysis of ATLAS and ATTAIN studies","volume":"6","author":"Wilson","year":"2017","journal-title":"Infect Dis Ther"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889318304206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889318304206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:52:14Z","timestamp":1760003534000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889318304206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S0732889318304206"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2018.09.011","relation":{},"ISSN":["0732-8893"],"issn-type":[{"type":"print","value":"0732-8893"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of telavancin against Staphylococcus aureus causing pneumonia or skin and skin structure infections with concomitant bloodstream infections in United States hospitals (2012\u20132016)","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2018.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}